Cui Bono?
I'm looking at you Pfizer and Moderna (especially Pfizer). And whoever you paid off.
The article gives the impression that Novavax's woes are due to having been only recently approved. But that's extremely misleading. Pfizer and Moderna received emergency authorization in late 2020. Novavax was a a couple of months behind on trials. The FDA apparently used that as an excuse not to give it emergency authorization. Meaning Novavax had to wait for final authorization, which takes a whole lot longer.
Sweeet deal for P and M when the FDA keeps a competitor off the market for a year and a half.
Novavax was my first choice because of its protein subunit design (vs mRNA). Instead of injecting something that hijacks your cells machinery to produce spikes, Novavax just injects the spikes with adjuvent and your body reacts to that.
It's not approved as a booster, either, so P and M maintain their shared monopoly.
Sure, it could be all on the up and up, but I'm skeptical.
Shares of COVID-19 vaccine maker Novavax cratered Tuesday as the U.S. biotech company slashed its sales forecast due to a slump in demand for its shots. The company's stock dived 31% after it cut its 2022 sales outlook in half.
Novavax's protein-based vaccine was a latecomer to the market. It was authorized by the Food and Drug Administration for use by adults in the U.S. only last month, long after a majority of adults had already been vaccinated with Pfizer, Moderna or Johnson & Johnson shots. Only 7,381 Novavax vaccine doses have been administered in the U.S., government data shows.
I'm looking at you Pfizer and Moderna (especially Pfizer). And whoever you paid off.
The article gives the impression that Novavax's woes are due to having been only recently approved. But that's extremely misleading. Pfizer and Moderna received emergency authorization in late 2020. Novavax was a a couple of months behind on trials. The FDA apparently used that as an excuse not to give it emergency authorization. Meaning Novavax had to wait for final authorization, which takes a whole lot longer.
Sweeet deal for P and M when the FDA keeps a competitor off the market for a year and a half.
Novavax was my first choice because of its protein subunit design (vs mRNA). Instead of injecting something that hijacks your cells machinery to produce spikes, Novavax just injects the spikes with adjuvent and your body reacts to that.
It's not approved as a booster, either, so P and M maintain their shared monopoly.
Sure, it could be all on the up and up, but I'm skeptical.
Novavax shares plunge on weak demand for its COVID-19 vaccine
Shares of COVID-19 vaccine maker Novavax cratered Tuesday as the U.S. biotech company slashed its sales forecast due to a slump in demand for its shots. The company's stock dived 31% after it cut its 2022 sales outlook in half.
Novavax's protein-based vaccine was a latecomer to the market. It was authorized by the Food and Drug Administration for use by adults in the U.S. only last month, long after a majority of adults had already been vaccinated with Pfizer, Moderna or Johnson & Johnson shots. Only 7,381 Novavax vaccine doses have been administered in the U.S., government data shows.
Novavax shares plunge on weak demand for its COVID-19 vaccine
Biotech CEO said he expects no new revenue for 2022 in the U.S. or through an international partnership.
www.cbsnews.com